Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial

医学 阿司匹林 冲程(发动机) 人口 临床试验 胃肠道出血 缺血性中风 随机对照试验 物理疗法 内科学 缺血 机械工程 环境卫生 工程类
作者
Yuesong Pan,Xia Meng,Baoshi Yuan,S. Claiborne Johnston,Hao Li,Philip M. Bath,Qiang Dong,Anding Xu,Jing Jing,Jinxi Lin,Yong Jiang,Xuewei Xie,Aoming Jin,Yue Suo,Hongqin Yang,Yefang Feng,Yanhua Zhou,Qing Liu,Xueli Li,Bin Liu
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:22 (6): 485-493 被引量:43
标识
DOI:10.1016/s1474-4422(23)00113-8
摘要

Background Aspirin is recommended for secondary stroke prevention in patients with moderate-to-severe ischaemic stroke but can lead to gastrointestinal intolerance and bleeding. Indobufen is used as an alternative antiplatelet agent in some countries, despite an absence of large-scale clinical trials for this indication. We tested the hypothesis that indobufen is non-inferior to aspirin in reducing the risk of new stroke at 90 days in patients with moderate-to-severe ischaemic stroke. Methods We conducted a randomised, double-blind, double-dummy, active control, non-inferiority trial at 163 tertiary and district general hospitals in China. Eligible participants were aged 18–80 years with acute moderate-to-severe ischaemic stroke (National Institutes of Health Stroke Scale score 4–18). We randomly assigned (1:1) participants within 72 h of the onset of symptoms to receive either indobufen (100 mg tablet twice per day) or aspirin (100 mg tablet once per day) for 90 days. The randomisation sequence was computer generated centrally and stratified by local participating centres. Masked local investigators assigned the random code to patients in ascending order and provided a treatment kit corresponding to the random code. The primary efficacy outcome was new stroke and the primary safety outcome was severe or moderate bleeding, both within 90 days. This primary efficacy outcome was assessed in all randomly assigned and consenting patients and in a per-protocol group (ie, all patients finishing the treatment without major violation of the trial protocol). Safety analyses were done in the safety-analysis population (ie, all patients who received at least one dose of the study drug and had a safety assessment available). We assessed the non-inferiority of indobufen versus aspirin using the one-sided upper limit of the 95% CI of the hazard ratio (HR) with a prespecified non-inferiority margin of 1·25. This trial is registered with ClinicalTrials.gov (NCT03871517). Findings This trial took place between June 2, 2019, and Nov 28, 2021. Of 84 093 patients screened, 5438 patients were randomly assigned to receive either indobufen (n=2715) or aspirin (n=2723), all of whom were included in the primary analyses. Median age was 64·2 years (IQR 56·1–70·6); 1921 (35·3%) were women and 3517 (64·7%) were men. Stroke occurred within 90 days in 213 (7·9%) patients in the indobufen group versus 175 (6·4%) in the aspirin group (HR 1·23, 95% CI 1·01–1·50; pnon-inferiority=0·44). Moderate or severe bleeding occurred in 18 (0·7%) patients in the indobufen group and in 28 (1·0%) in the aspirin group (0·63, 95% CI 0·35 to 1·15; p=0·13). Adverse events within 90 days occurred in 666 (24·5%) patients in the indobufen group and 679 (24·9%) patients in the aspirin group (p=0·73). Interpretation In patients with acute moderate-to-severe ischaemic stroke, indobufen was not non-inferior to aspirin because the upper limit of the 95% CI was greater than 1·25. Furthermore, indobufen seemed to be inferior to aspirin in reducing the risk of recurrent stroke at 90 days because the lower limit of the 95% CI was greater than 1·00. Although moderate or severe bleeding did not differ between groups, these findings do not support the use of indobufen for secondary stroke prevention in patients with moderate-to-severe ischaemic stroke. Funding Hangzhou Zhongmei Huadong Pharmaceutical and Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences. Translation For the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
纪秋完成签到 ,获得积分10
刚刚
Ellalala完成签到 ,获得积分10
刚刚
CipherSage的应助被师专第一黑奴采纳,获得10
1秒前
1秒前
1秒前
1秒前
科研通AI6.2的应助被Waitcy采纳,获得10
1秒前
霸气乐菱发布了新的文献求助10
2秒前
2秒前
3秒前
彩色青亦发布了新的文献求助10
3秒前
3秒前
果冻完成签到 ,获得积分10
4秒前
5秒前
6秒前
xushuqi给xushuqi的求助进行了留言
6秒前
cloudss完成签到,获得积分10
7秒前
勿语发布了新的文献求助10
8秒前
自信易槐完成签到,获得积分10
8秒前
Zhang发布了新的文献求助10
8秒前
科研通AI6.3的应助被dudu采纳,获得10
8秒前
9秒前
自由的百川完成签到 ,获得积分10
9秒前
9秒前
花花发布了新的文献求助10
10秒前
10秒前
10秒前
10秒前
852的应助被horse82采纳,获得10
11秒前
bby完成签到,获得积分20
11秒前
Bin发布了新的文献求助30
12秒前
13秒前
111发布了新的文献求助10
13秒前
zhongqiu关注了科研通微信公众号
14秒前
史文韬发布了新的文献求助10
14秒前
安详的飞鸟完成签到,获得积分10
14秒前
任雨净发布了新的文献求助10
15秒前
初景发布了新的文献求助10
15秒前
18秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194415
求助须知:如何正确求助?哪些是违规求助? 9580155
关于积分的说明 21870088
捐赠科研通 7793967
什么是DOI,文献DOI怎么找? 3437647
关于科研通互助平台的介绍 2560986
邀请新用户注册赠送积分活动 2484376